The interaction between antibodies and Immune cells surface FcγRIIIa (CD16a) receptor triggers a variety of immune responses including antibody-dependent cell-mediated cytotoxicity, antibody neutralization, phagocytosis, inflammation and tissue injury. Recent studies showed that IgG1 upper hinge region and FcγRs polymorphism play a major role in the interaction with Fcγ receptors and in the stability of the immune complex hence, in mounting strong inflammatory response. To further investigate this issue, we developed a tool box of IgG1 Fc isoforms to depict the affinity between mutated IgG1 Fc regions and extracellular domain variants (V158F) of CD16a. Our strategy consisted of designing different random upper-hinge mutated variants of IgG1 Fc domain, reproducing the naturally occurring two variants of CD16a and producing all of them as recombinant fusion proteins in Pichia Pastoris. The interactions were assayed using the Surface Plasmon Resonance (Biacore) method along with an in silico analysis to identify the major interaction and key residues that underline the affinity between the Fc region and CD16a variants. Our data showed that the affinity of the Fc region to the CD16a is strongly correlated to polar interactions. This molecular engineering approach yielded an IgG1Fc mutant with enhanced binding affinity to CD16a F158 variant.
Introduction
Interaction of the Fc moiety of immunoglobulin with the Fcγ receptors (FcγRs) on cell surface plays an important role in linking humoral and cellular branches of the immune system and it is one of the most important mechanisms by which antibodies can engage in inducing antibody-mediated cell cytotoxicity (ADCC). This ability of recruiting immune effector cells has long been investigated as a potential monotherapy treatment for several types of cancers and leukemia (Weiner et al., 2009 (Weiner et al., , 2012 Kato et al., 2016; Bang et al., 2017) and recently as a combinational strategy by combining ADCC therapy with chemotherapy, radiation and other targeted therapies (Morrissey et al., 2016) . In addition to the success in cancer treatment, ADCC therapy has been the center of attention for the treatment of several chronic diseases such as asthma (Nixon et al., 2017) , immune diseases such as AIDS (Margolis et al., 2017; Tomescu et al., 2017) and even elevated cholesterol and protection against anthrax inhalation (Reichert, 2016) .
Monoclonal antibody therapy has been established as one of the most successful treatment strategies and became dominant in the pharmaceutical market. Since the approval by the FDA in 1992 of the first monoclonal antibody (mAb), 68 more antibodies have been approved by 11 January 2017 (Cai, 2017) , and over 50 investigational monoclonal therapeutic antibodies are currently undergoing evaluation in late-stage clinical studies (Reichert, 2017) . By December 2017, 28 monoclonal antibodies reached late stage clinical studies evaluation for cancer treatment and 4 of which are expected to get approval by 2018 (Kaplon and Reichert, 2018) . Meanwhile, several studies investigated the role of FcγRs polymorphisms, as an integral part of ADCC, in the clinical outcome of monoclonal antibody therapy. Most of the therapeutic differences have been correlated to two germline CD16a polymorphisms, rs1801274 [CD16a; His(H)131Arg(R)] and rs396991 [CD16a;Phe(F)158Val(V)] and their pharmacogenomic association has been related to the outcome of several approved monoclonal antibodies such as Ritoximab (Burkhardt et al., 2016; Ajeganova et al., 2017; Falduto et al., 2017) Cetuximab (Weng and Levy, 2003; Chames et al., 2009; Liu et al., 2016) and HuHMFG1 ((MUC1)-targeting molecule) (Pandey and Namboodiri, 2014) . In most of these studies allotype CD16a V158 is the most comprehensively investigated and the results showed that patient with homozygous genotype V/V show higher biological and clinical responses.
In addition to the FcγRs' polymorphisms, scientist investigated the effect of IgG's hinge region structure on the binding affinity and hence the effector functions. The interaction between FcγRIIa and FcγRIIIa with antibody has been structurally solved and crystal structures of FcγRIIa and FcγRIIIa showed that the CD16a Ig-like domain consists of two domains (D1 and D2) with an angle of 50°between the two domains (Maxwell et al., 1999; Zhang et al., 2000) (Fig. 1) . When binding to an IgG antibody, only amino acids residues on D2 domain are directly involved in the binding to the Fc region. D1 domain is important for maintaining the D2 domain conformation. On the IgG Fc side the binding with the FcγRs involves the lower hinge region and the adjacent sites of the CH2 domain. During interactions, D1 and D2 domains of CD16a position into the opening of both Fc chains, which resembles a horseshoe. As a result, the hinge regions are pushed from a central location and lie almost perpendicular to the pseudo axis of the Fc chains (Radaev and Sun, 2001; Ramsland et al., 2011) . Even though the crystal structures showed that the direct interactions between IgG Fc domain and FcγRs involves CH2 domain and the lower hinge region only, the role of the upper hinge region of human IgG has also been studied. One study demonstrated the effect of upper hinge mutations on IgG1 that increased C1q binding and enhance CDC (Dall'Acqua et al., 2006) . Another study showed that substitution of His 229 residue with Tyr of the upper hinge region of IgG1 improves its stability, inhibited hinge cleavage by 98%, increased its binding with CD16a by 2-3-fold and improved ADCC by 2-fold (Yan et al., 2011) . Nowadays, Fc engineering technology is becoming the center of attention as an attractive approach to enhance the potency of therapeutic monoclonal antibodies. In this study, we describe the development of upper hinge IgG1Fc domain mutants that exhibit higher affinity to the CD16a phenylalanine variant. We used random mutations and in silico models to illustrate the relationship between affinity and polar interaction. Our data provide new insights into the molecular basis of the interaction between immunoglobulin IgG1 Fc region and Fc gamma receptors. It also yielded an IgG1 Fc moiety with enhanced affinity to CD16a F158 variant.
Experimental Procedures
Generation of recombinant IgG1 Fc moieties with mutated upper-hinge and recombinant F and V variants of the human CD16a receptor Bioinformatics tools were used to generate nine different expression plasmid constructs containing the extracellular domain of human CD16a variants (V158F), the wild type human IgG1 Fc region and six different random upper hinge mutated isoforms of human IgG1 Fc region (M1-M5 and M10) (Fig. 2) and (Table I ). The constructs including the restriction sites EcoRI and NotI were synthesized by GeneCust (Dudelange, Luxembourg) and cloned in P. pastoris expression vector pPICZαA (Invitrogen) downstream of the Saccharomyces cerevisiae Alpha factor signal sequence and in phase with a c-myc epitope and an additional 6X Histidine (His) tag on the 3'-end. The expression vectors were amplified in Escherichia coli Top 10 F´. The integrity of the purified plasmids was checked by 0.7% agarose gel electrophoresis stained with ethidium bromide, single and double restriction enzyme digest using EcoRI and NotI restriction enzymes and by the dye termination sequencing method (Sanger et al., 1977) done by GenoScreen Company, Lille, France. The sequencing was performed using universal AOX1 primers and sequences were analyzed by standard nucleotide Blast program.
Transformation of Pichia Pastoris
The recombinant expression vectors were linearized with BstX I (Promega) and purified by phenol chloroform method (Sambrook, 1989) followed by sodium acetate precipitation. Competent P. pastoris KM71H was prepared using condensed protocol (Lin-Cereghino et al., 2005) . Linearized vector was transformed into competent P. pastoris KM71H by electroporation (cuvette gap, 2.0 mm; charging voltage, 1500 V; resistance, 200 Ω; capacitance, 25 μF; Bio-Rad Gene Pulser). Transformants were selected on YPD plates supplemented with 500, 1000 and 2000 μg/ml Zeocin. After 72 h incubation at 30°C, single clones were picked and spotted on YPD plates containing 100 μg/ml Zeocin. Transformation was confirmed by colony PCR check using AOX1 primers: 5´AOX1:5´-GACTGGTTCCAATTGACAAGC-3´(forward primer) and 3´AOXI: 5´-GCAAATGGCATTCTGACATCC-3´(reverse primer).
Protein expression and purification
The expression of the recombinant proteins was methanol induced in EnPresso ® Yeast Defined Tablet Medium from BioSilta (Oulu, Finland) (Panula-Perala et al., 2008; Krause et al., 2010) . The expressed recombinant His-tagged proteins were purified from the supernatant using 5 ml HiTrap Chelating HP columns (GE Healthcare, UK). Different column was used for each recombinant clone. The columns are supplied free of metal ions and they were charged with Nickel ions (Ni
2+
) as a metal salt solution (0.1 M Ni 2 Cl). The supernatants were diluted with the binding buffer (1:1) and filtered through a 0.2 μm syringe filters (Pall Life Science, USA) before applying to the columns. 35-40 ml of the filtered supernatant were diluted up to 80 ml and were loaded on the column 20 ml per cycle. After applying the supernatants, the columns were washed with binding buffer to get rid of as much as possible of contaminants and the proteins were eluted by the elution buffer. The concentration of imidazole in the binding and the elution buffer differs according to the recombinant protein being purified. Different imidazole concentrations in both the binding buffer and elution buffer were tested for the best elution. For the CD16a variant 0 mM imidazole was added to the binding buffer and the protein was eluted in 20 mM imidazole (Ashoor et al., 2016) . For the Fc mutants 40 mM imidazole was used in the binding buffer and the protein was eluted in 500 mM imidazole.
Protein characterization, desalting and concentration
The purified proteins were characterized by Coomassie blue staining and silver staining on 15% SDS-PAGE (Bio-Rad laboratories, Hercules, USA). Western blot transfer was performed on PVDF membrane using wet/tank western blot (Bio-Rad laboratories, Hercules, USA) for 50-55 min. The membrane was incubated for 1 h in a blocking solution TBST (Tris-buffere saline pH 7.4, 0.1% Bovine serum albumin, 0.05% Tween 20) for CD16a variants and (Tris-buffere saline pH 7.4, 3% non-fat milk) for Fc mutants. Labeling was done by anti-His antibodies (1/5000) for CD16a. In the case of Fc wild type and its mutants, two antibodies were used primary antibody: Goat anti-human polyvalent immunoglobulin peroxidase conjugated (1/5000) incubated overnight at 4°C. The membrane was washed with blocking and TBS solution then the secondary antibody: Donkey anti-goat IgG-HRP (1/10 000) was added and incubated for 1 h at room temperature. Labeled proteins were detected by ECL western blotting detection reagent on Amersham Hyperfilm ECL sheets or by TMB (3,3',5,5'-tetramethylbenzidine) solution. Fractions exhibiting pure protein were pooled together and concentrated using Amicon Ultra-0.5 ml centrifugal filters. The salt was exchanged from the samples by dialysis method through cellulose membrane in an excess volume of phosphate buffer saline (PBS) pH 7.2 overnight at 4°C. Purified desalted proteins were stored at −70°C.
Surface plasmon resonance
Surface Plasmon Resonance experiments for measuring direct binding interactions were done at the Biacore Molecular Interactions Shared Resource of Lombardi Comprehensive Cancer Center at Georgetown University in Washington DC, USA. BiacoreT200 (GE Healthcare) was used to determine the kinetic parameters for the binding of Fc, M1, M2, M3, M4, M5 and M10 (ligands) with CD16aV and CD16aF (analytes). The experiments were performed using carboxymethyl-dextran (CM5) sensor chips. Initially, Protein A (Sigma, cat # P6031) was covalently attached to all the four flow cells of the sensor chip using amine coupling reaction. Flow cells 1, 2, 3, and 4 of the sensor chip were activated for 720 s at 10 μl/min with of 1:1 mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.5 M 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide hydrochloride (EDC). Stock Protein A (1.0 mg/ml) was diluted to 10 μg/ml (1:100 dilution) using 10 mM sodium acetate, pH 4.0 and injected over the activated flow cells at a flow rate of 10 μl/min flow rate for 600 s. After the immobilization of Protein A on all flow cells (~1500 RU)) the surfaces were deactivated by injecting 1 M ethanolamine for 720 s at 10 μl/min. The running buffer was PBS containing 0.05% Tween 20. For the first kinetic runs ligands were captured at a density of~1200 RU on flow cells 2, 3 and 4. Flow cell one was kept as a blank surface. Then kinetic runs were carried out using different concentrations (1024 nM, 512 nM, 256 nM, Fig. 2 Recombinant protein sequences. Substitution regions are indicated in bold. Underlined sequence is not included in the 3D models. CD16a V158, which were injected in triplicates. Each experiment was repeated at least two times. Data was analyzed with Biacore T200 Evaluation Software (version 1) using a 1:1 binding model.
In silico modeling and 3D structure analysis of Fc/CD16a complexes 3D modeling was performed using structural replacement using Pymol 1.3 (The PyMOL Molecular Graphics System. Version 1.5.0.4. Schrödinger). Solved model of the Fc/CD16a complex (PDB model 3SGJ) (resolution = 2.2°A) was used as a template model. Chains were dissociated and CD16a moiety was used to produce the two CD16a variants V and F at position 158. Builder and Mutagenesis functions of Pymol were used to extend the upperhinge region and introduce the amino acid modifications according to Table I on the Fc moiety of the model. Model refinement was performed using energy minimization by steepest descending provided by Swiss-Pdb viewer package prior to the Fc/CD16a complex rebuilding. Polar interactions were analyzed manually for each model using Pymol assuming a maximal distance of 3.5 Å between the donor and acceptor atoms.
For further investigation, Pymol generated Fc mutants and CD16a two variants structures were analyzed by docking study using Fc fragment as a Ligand and CD16a variant as a receptor. Docking was carried out using Hex 8.0.0 docking software (Ritchie et al., 2008) . The parameters used for the docking process were Correlation typeShape only, FFT Mode -3D, Post Processing-None, Grid Dimension −0.6, Receptor range −180, Ligand range −180, Twist range −360, Distance Range −40. After docking, solutions were screened and the generated complexes with the lowest total energy and RMSD to the PDB model 3SGJ were selected and polar interactions were analyzed manually for each model using Pymol assuming a maximal distance of 3.5 Å between the donor and acceptor atoms.
Results

Recombinant proteins design
Nine different proteins were designed and cloned in the expression vector pPICZαA. These proteins are the extracellular domain of the two variants CD16a variants V158F, the native IgG1 Fc region (hinge, CH2 and CH3) in addition to six different upper hinge mutated forms of the human IgG1 Fc moiety. Upper hinge substitution in mutant M10 is a reproduction of that described by Yan et al. (2011) (Table I) .
Purified recombinant proteins
Collected concentrated proteins were analyzed with coomassie brilliant blue and silver staining SDS-Page and western blotting. The sizes of the bands on both SDS-Page and the western blot were consistent with the predicted glycosylated fusion proteins. Purified recombinants CD16a showed sharp band on SDS-PAGE and western blot at~45 kDa (Fig. 3a) where Fc mutants showed bands at 50 kDa (dimer) (Fig. 3b) and~25 kDa (monomer).
Binding affinity
Direct binding interactions between upper hinge Fc domain mutants and the two variants of CD16a were measured by Biacore. The Fc domain was used as ligand and CD16a isoforms as analytes (Fig. 4) . The kinetic parameters: association constant (Ka), dissociation constant (Kd), and equilibrium dissociation constant KD (μM) were calculated. The data showed that mutants M1 and M2 display higher affinity for CD16a F158 variant as compared to the V158 variant (Table I) .
3D modeling analysis
The interaction in the 3D model of Fc/CD16a complex is in an asymmetric mode, where CD16a binds IgG1 Fc between the two CH2 domains and lower hinge region at the center of the horse shoe opening establishing contacts to the lower hinge regions of both A and B chains of Fc. This binding breaks down the symmetry of the Fc creating an asymmetric interface whereby the identical residues from lower Hinge-A and Hinge-B interact with different, unrelated surfaces of the receptor (Fig. 1a, b) . In addition, middle and upper hinge regions were pushed from a central location and lie almost perpendicular to the pseudo-2-fold axis of the Fc and directed away from the CD16a binding site (Fig. 1c) . compared to the V158 variant (Fig. 5) . Comparing polar interactions in the generated complexes between CD16a variants with mutant Fc domain showed that all the CD16a V158 complexes exhibit the same polar interactions as the wild type complex (Table II) and His 135 of the CD16a F158, respectively) (Table III) .
Complexes protein-protein polar interaction analysis
Docking analysis of Fc fragments and CD16a variants confirmed the results obtained by structural replacement results. In fact, interactions between wild type IgG1 Fc and the CD16a F158 variants differ by the presence of two polar interactions in the complex (Ser239 from chain A and Gly236 from chain B of the Fc domain with Lys120 and Lys161 of the CD16a F158 respectively). In addition, our docking approach showed a polar contact that is present between Fc wild type and CD16a V158 and F158 variants (Gly 236 of the Fc domain with His 135 of the CD16a). This same interaction was present in the M1 and M2 mutants when interacting with the CD16a F158 variant but absent in the other mutants.
Discussion
To get more insights into the molecular basis of the interaction between the IgG1 Fc region and the CD16a receptor and to investigate the effect of the CD16a V158F polymorphism on this interaction, we developed a molecular engineering approach which consisted in developing a tool box of IgG1 Fc isoforms to lay out the affinity between upper-hinge mutated IgG1 Fc regions and extracellular domain variants (V158F) of CD16a. Indeed, we designed, cloned and expressed human extracellular domains of CD16a V158F and different mutants of the constant domain of IgG1 (Hinge, CH2 and CH3) in Pichia pastoris. The secreted recombinant protein of the extracellular domain of CD16a (V158F) variants consisted of 191 amino acids (position 17-208) (Ravetch and Perussia, 1989) and have a predicted molecular weight of~21 kDa. The molecular weights obtained on SDS were~45 kDa indicating potential glycosylation. Human Fc domain variants are consisting of 232 amino acids (position 99-330) including hinge region, CH2 and CH3 chains, with predicted molecular mass of~25 kDa. Upper hinges were randomly mutated creating six mutants (M1-M5 and M10). The additional M10 mutant was designed based on published data (Yan et al., 2011) . All mutants and the wild type Fc domains were expressed in P. pastoris. SDS analysis and western blotting showed a~50 kDa protein for Fc region and its mutants and show the occurrence dimerization of the two Fc heavy chains.
Surface plasmon resonance (Biacore) analysis of the Fc/CD16a interaction revealed an upper hinge mutants exhibiting increased binding affinity with CD16a phenylalanine variant (F158). Indeed, both CD16a variants exhibit almost the same affinity with the wild type IgG1 Fc domain. This data was unexpected in this respect that the literature (Koene et al., 1997; Congy-Jolivet et al., 2008 ; In parallel with the experimental part of the study, we generated in silico models to represent the interaction of Fc domain and Fcγ receptors. These models were used to evaluate the effect of the Fc upper hinge mutations and different variants of CD16a on the polar interactions of the complexes. Our data obtained by structural replacement and docking analysis pointed to differences in polar interactions between recombinant CD16a variants with the wild type and mutated forms of IgG1 Fc region as being a key in defining the interaction affinity. Indeed, we generated an upper hinge engineered recombinant IgG1 Fc domains with high affinity to the low binding allele of CD16a (F/F158), mutant M1 and M2. Polar interaction analysis of these two mutants (M1 and M2) confirm our preliminary findings where mutant M1 exhibit the exact interactions found with CD16a V158 variant, and M2 has an extra polar interaction between Gly 129 and Ser
298
. The affinity analysis of M1 and M2 showed an increase in affinity to CD16a F158 variant by almost 3.3-fold and 2.7-fold, respectively, compared to the affinity with the wild type Fc. Mutants M3, M4, M5 and M10 showed a very low affinity with the two variants CD16a. On a structural level we found that these mutants are missing a polar interaction between His 135 on CD16a and Gly 236 on chain A of the Fc mutants. This position of Gly 236 in the lower hinge of human IgG1 is well known to be the location of cleavage with IdeS protease of Streptococcus pyogenes (Brezski et al., 2014) . Variations at Gly 236 have been described to cause conformational changes in the lower hinge region of bound Fc and mutations at this location affects the binding with FcγRs (Richards et al., 2008; Ahmed et al., 2016 ), it has been described to have 3.1 times higher binding to CD16a F158 and 2.2 times higher binding to CD16a V158 based on ELISA test, and has an improved ADCC activity by two folds (Yan et al., 2011) . Interestingly, our data showed that M10 exhibit lower binding affinity with both variants of CD16a based on the KD values. This observation raises the question of the exact relationship between ADCC and ELISA assay measured on a cellular level and actual antibody affinity based on protein-protein interactions.
The data from this study confirm those published about the involvement of the human IgG's Fc moiety upper hinge region in defining the affinity of the interaction between antibodies and Fc gamma receptor expressed on the surface of immune effector cells. It also shed light on the importance of different remote sites (mutations away from the binding site) on the interaction of IgG1 with its Fcγ receptors and hence antibody effector functions. In addition, our study presents a feasible and adequate approach for the generation of therapeutic antibodies endowed with high ADCC function through Fc region engineering and computational design algorithms. These methods allow the understanding of the molecular basis of interaction between therapeutic monoclonal antibodies and FcγRs allowing more targeted immunotherapies. In addition we showed that IgGs upper hinge, although functionally distinct from the actual binding site, plays an important role in the antibody effector function. 
